Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy


      News provided by

      Ractigen Therapeutics

      Oct 03, 2026, 07:30 ET

      Share this article

      Share this article


      • First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease.
      • Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal utrophin expression, accompanied by definitive tissue histopathological remodeling
      • Concordant positive trajectories observed across motor and pulmonary functional endpoints
      • Favorable safety and tolerability profile demonstrated, with zero dose-limiting toxicities (DLTs) and zero serious adverse events (SAEs)
      • Cohort 2 (30 mg) fully enrolled

      HIROSHIMA, Japan and NANTONG, China, Oct. 3, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biotechnology company pioneering RNA activation (RNAa) therapeutics, today presented positive first-in-human clinical data from its ongoing Phase I trial of RAG-18 (NCT07282652) during a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society (WMS 2026), held in Hiroshima, Japan.

      The data establish the first clinical proof-of-mechanism for RNA activation (RNAa) in a human monogenic disease, demonstrating that a systemically delivered saRNA can safely enter human skeletal muscle and upregulate an endogenous, therapeutically relevant target protein.

      The presentation, titled "First-in-human evidence of RNA activation-mediated sarcolemmal utrophin upregulation in Duchenne muscular dystrophy," was delivered orally by the study's Principal Investigator, Professor Yi Dai, MD, PhD, Department of Neurology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences.

      For more than two decades, the neuromuscular field has recognized utrophin — a naturally occurring structural relative of dystrophin — as one of the most compelling therapeutic ideas in DMD. Because utrophin can substitute for dystrophin at the muscle membrane regardless of which DMD mutation a patient carries, sufficiently increasing it would represent a mutation-independent approach relevant to the entire patient population. The historical obstacle was never the biology, but the absence of a modality capable of safely switching on endogenous gene transcription directly in human muscle. The data presented today directly demonstrate how RNAa overcomes this longstanding barrier.

      RAG-18 is developed on Ractigen's proprietary RNAa platform and delivered using the company's Lipid-Conjugated Oligonucleotide (LiCO™) technology as an aqueous saline formulation via monthly intravenous (IV) infusion. It harnesses the cell's endogenous transcriptional machinery to increase utrophin production without viral vectors or permanent DNA editing. RAG-18 has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA).

      Professor Yi Dai, MD, PhD, Principal Investigator, commented:
      "In the first three boys treated, we observed a complete and internally consistent chain of evidence: paired muscle biopsies showed utrophin robustly upregulated and correctly localized at the sarcolemma, muscle architecture improved with less fibrosis and fat infiltration, and motor and pulmonary measures held steady or improved over the same window. What is particularly striking is that these three boys carry three different types of DMD mutations, yet all showed signals in the same direction — a clinical illustration of what a mutation-independent strategy means in practice. As a clinician who has cared for patients with neuromuscular disease for many years, being part of this first human validation from mechanism to tissue to function is deeply encouraging."

      Long-Cheng Li, MD, Founder, Chairman and Chief Executive Officer of Ractigen Therapeutics, added:
      "The data presented today at WMS establish the first clinical proof-of-mechanism for RNA activation. With rigorous patient-level evidence, we have shown that saRNA can reliably activate an endogenous target gene in human skeletal muscle and drive repair at the tissue level. This is a milestone not only for the RAG-18 program but for the field of RNA medicine, which can now move beyond silencing genes to switching them on. RAG-18 has the potential to become a disease-modifying therapy for patients across all DMD genotypes. With Cohort 2 fully enrolled, we are committed to accelerating clinical development so that this pioneering therapy can reach patients worldwide as soon as possible."

      Key Highlights from the WMS Late-Breaking Presentation (NCT07282652):
      The open-label, dose-escalation first-in-human trial is evaluating the safety, tolerability, pharmacodynamics, and exploratory efficacy of RAG-18 in ambulatory boys aged 4–15 with genetically confirmed DMD. The presentation reported multi-dimensional data through Day 169 from Cohort 1 (15 mg monthly IV, n=3):

      • Favorable Safety & Tolerability: There were zero dose-limiting toxicities (DLTs), zero serious adverse events (SAEs), and no Grade ≥3 treatment-emergent adverse events (TEAEs). All reported adverse events were mild (Grade 1–2), transient, and resolved spontaneously without medical intervention. No dose interruptions, reductions, or discontinuations occurred.
      • Robust & Precise Sarcolemmal Target Engagement: Paired contralateral muscle biopsies at Day 113 analyzed via whole-field quantitative immunofluorescence (IF) revealed a 3.5- to 5.3-fold upregulation of sarcolemmal utrophin signal density in mature myofibers (and a 4.1- to 4.7-fold increase in regenerating myofibers) compared to pre-dose baseline. Co-staining with laminin confirmed precise and uniform localization to the sarcolemma.
      • Histopathological Structural Remodeling: Morphometric analysis at Day 113 showed increased mean myofiber cross-sectional area (+5% to +15%) and mean myofiber diameter (+5.34 μm to +27.50 μm) without evidence of drug-induced myonecrosis or inflammation. Muscle fat fraction decreased by 3% to 10%, indicating tissue stabilization.
      • Reduction of Active Tissue Edema: Quantitative muscle MRI (qMRI) revealed reductions in thigh muscle T2 relaxation times (up to −11.6% at Day 169), consistent with the resolution of active muscle edema and inflammation.
      • Positive Functional & Pulmonary Trajectories:
        • Pulmonary Signals:  All three participants showed positive numerical trends in spirometric parameters over 24 weeks, with percent predicted forced vital capacity (FVC%) increasing by +2.8% to +41.0% and forced expiratory volume (FEV1%) by +2.8% to +34.0%.
        • Ambulatory Trajectories: In an early-ambulatory participant (age 6.8), 6-minute walk distance (6MWD) improved by +36.5 m. In a late-ambulatory participant (age 12.7), 6MWD remained preserved (−1.0 m delta) alongside improved 4-stair climb time. Participant 1 (age 7.3) experienced a decline of −62.5 m in 6MWD. NSAA scores declined uniformly by −3 points across all three participants, underscoring the heterogeneous and progressive nature of DMD motor function.
        • Cardiac Function: Left ventricular ejection fraction (LVEF) remained within normal limits (≥55%) across all participants throughout the 24-week follow-up.

      Clinical Program Update
      Cohort 2 (30 mg monthly IV) is fully enrolled and safety follow-up is ongoing as planned.

      About Duchenne Muscular Dystrophy (DMD)
      DMD is a rare, severe, X-linked progressive neuromuscular disorder caused by mutations in the DMD gene that result in deficiency or absence of dystrophin, a protein essential to protecting muscle fibers from contraction-induced injury. Affected boys experience progressive muscle degeneration, loss of ambulation, respiratory insufficiency and cardiomyopathy. Utrophin is a structural and functional homolog of dystrophin, highly expressed during fetal development; increasing endogenous utrophin is a mutation-agnostic strategy with the theoretical potential to be relevant to patients across all DMD genotypes.

      About RAG-18
      RAG-18 is an investigational small activating RNA (saRNA) developed on Ractigen's proprietary RNAa platform. Administered systemically, RAG-18 targets regulatory regions of the human UTRN gene to induce nuclear, Argonaute-dependent transcriptional activation, increasing endogenous utrophin production. RAG-18 is currently being evaluated in an ongoing first-in-human, open-label, dose-escalation clinical trial (NCT07282652).

      About Ractigen Therapeutics
      Ractigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™, and GLORY™, Ractigen is advancing a robust pipeline addressing unmet medical needs in oncology, neurological diseases, and genetic disorders. Its versatile technologies also enable the rapid development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics. For more information, visit www.ractigen.com, and follow us on X and LinkedIn.

      SOURCE Ractigen Therapeutics

      Modal title

      Also from this source

      Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer

      Ractigen Therapeutics, a leading clinical-stage biopharmaceutical company developing innovative small activating RNA (saRNA) therapeutics, today...

      Ractigen Therapeutics Publishes Foundational Study on its Extrahepatic LiCO™ Delivery Platform in Molecular Therapy - Nucleic Acids

      Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) and targeted oligonucleotide therapeutics,...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Pharmaceuticals

      Pharmaceuticals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.